

# **The Emergence of a Cluster? The Biotechnology Community in London, Ontario**

---

Dean A. Hennessy

Rotman School of Management  
University of Toronto

ISRN Conference  
May 2003

---

# Introduction

---

## Research Question:

- (1) When is a cluster a cluster? Does the biotech community in London, Ontario constitute a cluster?
- (2) How does a cluster emerge, and how do community level resources and linkages facilitate or impede their growth and development?

- Plan:
    - Theory
    - Research setting/design
    - Next Steps
-

# Theoretical Background

---

What is a cluster?:

- Measures of clustering:
    - Counts of firms in an industry
    - Relative concentration of an industry in a region
  - Standard story: positive externalities  $\Rightarrow$  agglomeration
  - Evidence that few industries are concentrated in a way other than what could be described as random (*Ellison & Glaeser, 1997*)
  - Higher degree of clustering in knowledge intensive industries (*Swan & Prevezer, 1996*)
    - Cost/risk minimization; knowledge sharing/learning/spillovers
  - Fundamental identification problem with all emergent phenomena:
    - Can it only be identified as such after it becomes fully realized?
    - Or, are there stages that can be identified?
  - Why is understanding clustering as a dynamic phenomenon important?
    - policy
-

# Theoretical Background

---

## Organizational Emergence:

- Two primary mechanisms for (localized) emergence:
    - Start-ups: most likely to emerge from the localized environment (*Feldman, 2001; Klepper, 2001; Zucker, et al., 1998*) inheritance with variation (*Winter, 1990*)
    - (re)-location (eg. branch plants): knowledge seeking as a motivation for location choice (*Chung & Alcacer, 2002*); self-selection (*Shaver, 1998*)
  - Startups are more sensitive to their local environments: especially due to legitimacy and competition (*Lomi, 1995*)
  - Institutional transfer - from the academy to the economy:
    - Knowledge transfer is facilitated by:
      - university policy (*Zucker, et al., 2002*)
      - Culture of entrepreneurship in the academy (*Audretsch, 2000*); entrepreneurship in the community (*Feldman, 2001*);
-

# Theoretical Background

---

- Coevolution
    - co-evolution between industry, technology and supporting institutions (*Nelson, 1998*)
    - There are positive feedback economies from agglomeration (*Arthur, 1988*); the more agglomerated, the more the region becomes a basin of attraction, leading to:
      - more institutional supports: new institutions; enhanced resources at local institutions
      - more intermediate suppliers;
      - more specialized labour flows
    - These reinforce the agglomeration of industry in a particular region; more specialized labour lowers the labour constraint; more intermediate suppliers lowers costs; increases institutional supports.
-

# Research Setting

---

## Characteristics of the Biotechnology Industry:

- Highly heterogeneous:
    - research fields: agriculture, biological, medical
    - Industry fields: agriculture, chemicals, diagnostics, therapeutics, etc.
  - technologically intensive industry:
    - Perpetual knowledge generation at the industry level
    - Highly innovative: patenting is a common activity
    - Long lead times in bringing new products to market; highly uncertain outcomes
    - Alliances are a prominent feature of biotech industry, of which there are two main types:
      - Research alliances: combines the tacit knowledge of the partners
      - Commercial alliances: focuses on marketing and distribution
    - Institutions: local and national
-

# Research Setting

---

## Data:

- interviews of key personnel in organizations in London: firms, research institutes, universities/hospitals, VCs, civic associations, government agencies.
-

# Research Setting

---

## Biotechnology in London, ON:

– Roughly 40 firms

- Research and industry fields: biomedical devices, biotechnology, bioinformatics, pharmaceuticals.
  - Institutions: LHSC, UWO, LRCC, NCA, CHRI, NRC(IMTI), RRI, LHRI (core research); LBCC
  - Policy: federal/provincial funding used to promote the development of the sector (CFI, CIHR)
-

# Research Setting

---

## Biotechnology in London, ON:

- **UWO** was recently awarded \$4.8 million of research infrastructure funding from the **CFI** for development of projects including **Biomedical Engineering** and the **Advanced Biotechnology Research Centre**. The U.S. based Whitaker Foundation also awarded UWO \$1.4 million to assist with the establishment of a graduate program in biomedical engineering.
  - G. Scott Paterson, the Chairman and CEO of Yorkton Securities Inc., donated \$1 million to UWO for a new biotechnology wing in the Medical Sciences Building.
  - In July of 2000, LHSC was awarded over \$6 million dollars in grants from the **CFI** and the Ontario government to create the **National Centre for Minimally Invasive Robotic Surgery**.
-

# Summary of Observations:

---

- Most of the startups in the region were spunoff of local institutions
  - Strong institutional linkages remain
  - There are emerging commercialization capabilities in the region, and an entrepreneurial culture
  - There is evidence of the coevolution of industry, institutions (and probably technology):
    - Much federal and provincial funding supporting the development of the local industry
    - Local institutions adapting to policy and industry demands
    - Firms adapting to the local institutions
    - Presence of local industry and civic entrepreneurs
-

# London, ON – the downside...

---

- Few inter-firm linkages (high degree of differentiation in products/ technologies)
  - Few firms are locating in, or setting up branches in London because of the biotech community
  - Financing: some VCs located there but do not necessarily serve the local market
  - Transportation is underdeveloped
  - Proximity to another biotech region: “That great sucking sound from Toronto”
  - Perception of entrepreneurship is still lacking
-

**So...**

---

Is this a cluster?

---

# Next Steps:

---

- Theory refinement
  - Data collection
    - More interviews/construction of the genealogy of the community
    - archival data of the whole biotech industry in Canada since its inception
      - Firm level CMA level
      - Ties – by partner: to firms, institutions, etc.; R&D consortia; by type: research, commercialization alliances, licensing agreements
      - Spillovers: Patents/products
      - Community characteristics: Institutional, etc.
-

**Figure 1: A Model of a Regional System of Innovation**

